Epidemiological Factors Associated With Intraductal Papillary Mucinous Neoplasm of the Pancreas: A Dual Center Case-Control Study.
Journal
Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542
Informations de publication
Date de publication:
01 03 2022
01 03 2022
Historique:
entrez:
18
5
2022
pubmed:
19
5
2022
medline:
21
5
2022
Statut:
ppublish
Résumé
The present study aimed to identify epidemiological factors associated with the development of intraductal papillary mucinous neoplasms (IPMN) of the pancreas comparing patients after IPMN resection with population-based controls. Preoperative data of 811 patients undergoing pancreatic resection for IPMN were matched in a 1:1 ratio with a random sample of volunteers from the Study of Health in Pomerania, which showed no pancreatic cyst greater than 2 mm in magnetic resonance cholangiopancreaticography. A total of 811 controls with a mean age of 61.9 years (standard deviation, 8.4 years) were matched to cases with a mean age of 66.1 years (standard deviation, 9.3 years). A previous history of pancreatitis, endocrine pancreatic insufficiency was significantly more frequent in IPMN patients compared with controls (P = 0.001). Moreover, adjusted data revealed that urogenital cancer (P = 0.034), colorectal cancer (P = 0.021), as well as first-degree family history of colorectal cancer (P = 0.001) were significantly more frequent in IPMN patients. A history of urogenital and colorectal cancer often coincides with IPMN, which have an indication for surgery and are associated with preoperative episodes of pancreatitis and with endocrine insufficiency. Prospective studies are needed to investigate the role of these factors in IPMN development.
Identifiants
pubmed: 35584382
doi: 10.1097/MPA.0000000000002007
pii: 00006676-202203000-00006
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
250-255Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
WHO International Agency for Research on Cancer. GLOBOCAN—cancer tomorrow. Global Cancer Observatory. 2020. Available at: http://gco.iarc.fr/tomorrow/home . Accessed December 9, 2019.
Hank T, Hinz U, Tarantino I, et al. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail. Br J Surg . 2018;105:1171–1181.
Klaiber U, Leonhardt CS, Strobel O, et al. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer. Langenbecks Arch Surg . 2018;403:917–932.
de Pretis N, Mukewar S, Aryal-Khanal A, et al. Pancreatic cysts: diagnostic accuracy and risk of inappropriate resections. Pancreatology . 2017;17:267–272.
Hackert T, Fritz S, Klauss M, et al. Main-duct intraductal papillary mucinous neoplasm: high cancer risk in duct diameter of 5 to 9 mm. Ann Surg . 2015;262:875–880; discussion 880–881.
Oyama H, Tada M, Takagi K, et al. Long-term risk of malignancy in branch-duct intraductal papillary mucinous neoplasms. Gastroenterology . 2020;158:226–237.e5.
Pergolini I, Sahora K, Ferrone CR, et al. Long-term risk of pancreatic malignancy in patients with branch duct intraductal papillary mucinous neoplasm in a referral center. Gastroenterology . 2017;153:1284–1294.e1.
Basturk O, Hong SM, Wood LD, et al. A revised classification system and recommendations from the Baltimore consensus meeting for neoplastic precursor lesions in the pancreas. Am J Surg Pathol . 2015;39:1730–1741.
Kim JH, Eun HW, Park HJ, et al. Diagnostic performance of MRI and EUS in the differentiation of benign from malignant pancreatic cyst and cyst communication with the main duct. Eur Radiol . 2012;81:2927–2935.
European Study Group on Cystic Tumours of the Pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut . 2018;67:789–804.
Fernández-del Castillo C, Adsay NV. Intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology . 2010;139:708–713, 713.e1–e2.
Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology . 2006;6:17–32.
Tanaka M, Fernández-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology . 2012;12:183–197.
Völzke H, Alte D, Schmidt CO, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol . 2011;40:294–307.
Hegenscheid K, Kühn JP, Völzke H, et al. Whole-body magnetic resonance imaging of healthy volunteers: pilot study results from the population-based SHIP study. Rofo . 2009;181:748–759.
Bülow R, Simon P, Thiel R, et al. Anatomic variants of the pancreatic duct and their clinical relevance: an MR-guided study in the general population. Eur Radiol . 2014;24:3142–3149.
Weiss FU, Budde C, Lerch MM. Specificity of a polyclonal fecal elastase ELISA for CELA3. PloS One . 2016;11:e0159363.
Amanquah SD, Darko R, Maddy SQ, et al. Faecal pancreatic elastase–1 a non invasive measure of exocrine pancreatic function. West Afr J Med . 2004;23:240–244.
Crippa S, Fernández-del Castillo C. Management of intraductal papillary mucinous neoplasms. Curr Gastroenterol Rep . 2008;10:136–143.
Crippa S, Fernández-Del Castillo C, Salvia R, et al. Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol . 2010;8:213–219.
Jais B, Rebours V, Malleo G, et al. Serous cystic neoplasm of the pancreas: a multinational study of 2622 patients under the auspices of the International Association of Pancreatology and European Pancreatic Club (European Study Group on Cystic Tumors of the Pancreas). Gut . 2016;65:305–312.
Kromrey ML, Bülow R, Hübner J, et al. Prospective study on the incidence, prevalence and 5-year pancreatic-related mortality of pancreatic cysts in a population-based study. Gut . 2018;67:138–145.
Capurso G, Boccia S, Salvia R, et al. Risk factors for intraductal papillary mucinous neoplasm (IPMN) of the pancreas: a multicentre case-control study. Am J Gastroenterol . 2013;108:1003–1009.
Leal JN, Kingham TP, D'Angelica MI, et al. Intraductal papillary mucinous neoplasms and the risk of diabetes mellitus in patients undergoing resection versus observation. J Gastrointest Surg . 2015;19:1974–1981.
Mayerle J, Kraft M, Menges P, et al. [Intraductal papillary mucinous neoplasia: which findings support observation?]. [Article in German]. Chirurg . 2012;83:123–129.
Tanaka M. Clinical management and surgical decision-making of IPMN of the pancreas. Methods Mol Biol . 2019;1882:9–22.
Dominguez-Muñoz JE. Diagnosis and treatment of pancreatic exocrine insufficiency. Curr Opin Gastroenterol . 2018;34:349–354.
Baumgaertner I, Corcos O, Couvelard A, et al. Prevalence of extrapancreatic cancers in patients with histologically proven intraductal papillary mucinous neoplasms of the pancreas: a case-control study. Am J Gastroenterol . 2008;103:2878–2882.
Reid-Lombardo KM, Mathis KL, Wood CM, et al. Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management. Ann Surg . 2010;251:64–69.